Literature DB >> 18820370

Phosphoproteome and transcriptome analyses of ErbB ligand-stimulated MCF-7 cells.

Takeshi Nagashima1, Masaaki Oyama, Hiroko Kozuka-Hata, Noriko Yumoto, Yoshiyuki Sakaki, Mariko Hatakeyama.   

Abstract

Cellular signal transduction pathways and gene expression are tightly regulated to accommodate changes in response to physiological environments. In the current study, molecules were identified that are activated as a result of intracellular signaling and immediately expressed as mRNA in MCF-7 breast cancer cells shortly after stimulation of ErbB receptor ligands, epidermal growth factor (EGF) or heregulin (HRG). For the identification of tyrosine-phosphorylated proteins and expressed genes, a SILAC (stable isotopic labeling using amino acids in cell culture) method and Affymetrix gene expression array system, respectively, were used. Unexpectedly, the overlapping of genes appeared in two experimental datasets was very low for HRG (43 hits in the proteome data, 1,655 in the transcriptome data, and 5 hits common to both datasets), while no overlapping gene was detected for EGF (15 hits in the proteome data, 211 hits in the transcriptome data, and no hits common to both datasets). The HRG overlapping genes included ERBB2, NEDD9, MAPK3, JUP and EPHA2. Biological pathway analysis indicated that HRG-stimulated molecular activation is significantly related to cancer pathways including bladder cancer, chronic myeloid leukemia and pancreatic cancer (p < 0.05). The proteome datasets of EGF and HRG contain molecules that are related to Axon guidance, ErbB signaling and VEGF signaling at a high rate.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18820370

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  8 in total

Review 1.  CAS proteins in normal and pathological cell growth control.

Authors:  Nadezhda Tikhmyanova; Joy L Little; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2009-11-25       Impact factor: 9.261

2.  A requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 mice.

Authors:  J L Little; V Serzhanova; E Izumchenko; B L Egleston; E Parise; A J Klein-Szanto; G Loudon; M Shubina; S Seo; M Kurokawa; M F Ochs; E A Golemis
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

3.  NEDD9 promotes oncogenic signaling in mammary tumor development.

Authors:  Eugene Izumchenko; Mahendra K Singh; Olga V Plotnikova; Nadezhda Tikhmyanova; Joy L Little; Ilya G Serebriiskii; Sachiko Seo; Mineo Kurokawa; Brian L Egleston; Andres Klein-Szanto; Elena N Pugacheva; Richard R Hardy; Marina Wolfson; Denise C Connolly; Erica A Golemis
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

4.  Proteomics in pancreatic cancer research.

Authors:  Ruihui Geng; Zhaoshen Li; Shude Li; Jun Gao
Journal:  Int J Proteomics       Date:  2011-08-14

Review 5.  Cas proteins: dodgy scaffolding in breast cancer.

Authors:  Giusy Tornillo; Paola Defilippi; Sara Cabodi
Journal:  Breast Cancer Res       Date:  2014       Impact factor: 6.466

Review 6.  Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.

Authors:  Anna E Kersh; Maiko Sasaki; Lee A Cooper; Haydn T Kissick; Brian P Pollack
Journal:  Front Pharmacol       Date:  2016-09-26       Impact factor: 5.810

7.  Linking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling.

Authors:  Shao-shan Carol Huang; David C Clarke; Sara J C Gosline; Adam Labadorf; Candace R Chouinard; William Gordon; Douglas A Lauffenburger; Ernest Fraenkel
Journal:  PLoS Comput Biol       Date:  2013-02-07       Impact factor: 4.475

8.  Role of NEDD9 in invasion and metastasis of lung adenocarcinoma.

Authors:  Jing-Xia Chang; Feng Gao; Guo-Qiang Zhao; Guo-Jun Zhang
Journal:  Exp Ther Med       Date:  2012-09-03       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.